Achieving the latest American Heart Association and American College of Cardiology therapeutic goals for hypertension with combination therapy and its effects on blood pressure and central hemodynamic parameters

C. Venkata S. Ram*, Baby Shalini Muppalla, Sarvepalli Vijaya Parthasaradhi, Gajjela Praveen Kumar, Saumitra Ray, Uday Jadhav, J. P. S. Sawhney, Govindan Unni, Nagaraj Desai, Members of the TelCom Study Group

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The present United States and European treatment guidelines recommend that antihypertensive therapy be initiated with a combination of agents from different classes to facilitate the achievement of control of blood pressure (BP). This prospective, randomized, open-label study was conducted at 3 tertiary hospitals in India to evaluate the effects of combination therapy with an angiotensin receptor blocker and a calcium antagonist on office BP and central hemodynamic parameters in patients with untreated hypertension or uncontrolled BP (>130/>80 mm Hg) during treatment with antihypertensive monotherapy. Patients were randomized to treatment with telmisartan 40 mg/day + amlodipine 5 mg/day or telmisartan 40 mg/day + cilnidipine 10 mg/day. Change from baseline to 8 weeks of treatment was assessed for seated office BP, ambulatory BP monitoring, and seated central hemodynamics (central BP, aortic augmentation index, central aortic augmentation pressure, and pulse wave velocity). A total of 94 of 96 enrolled patients completed the study. From baseline to 8 weeks a significant decrease was observed in both telmisartan + amlodipine and telmisartan + cilnidipine groups for mean BP (148.0 ± 12.80 to 124.0 ± 10.4 and 144.5 ± 10.2 to 123.0 ± 10.0 mm Hg, respectively; both p <0.001); in only telmisartan + amlodipine group for mean central aortic systolic and diastolic BP (131.1 ± 19.1 to 119.7 ± 14.9 mm Hg [p <0.001] and 93.3 ± 12.0 to 89.2 ± 14.6 mm Hg [p = 0.0008], respectively) and for central aortic pulse wave velocity (7.6 ± 1.4 to 7.2 ± 1.3 m/s, p = 0.0011); in only telmisartan + cilnidipine group for aortic augmentation index (27.5 ± 14.6 to 22.3 ± 12.2; p = 0.0178). Heart rate was unchanged in both treatment groups. Combination therapy with an angiotensin receptor blocker and a calcium antagonist effectively reduced BP to below the new <130/80 mm Hg target and had favorable effects on central hemodynamics.

Original languageEnglish
Pages (from-to)78-82
Number of pages5
JournalAmerican Journal of Cardiology
Volume168
DOIs
Publication statusPublished - 1 Apr 2022

Fingerprint

Dive into the research topics of 'Achieving the latest American Heart Association and American College of Cardiology therapeutic goals for hypertension with combination therapy and its effects on blood pressure and central hemodynamic parameters'. Together they form a unique fingerprint.

Cite this